It has been reported that the prevalence of BRAF V600E mutations in patients with PTC coexisting with HT is significantly lower than in those without HT, and the activity of the MAPK signaling pathway—such as the expression level of phosphorylated ERK (p-ERK)—is also markedly reduced (27, 41). The gene discussed is BRAF; the disease is hematocrit.